Literature DB >> 22395697

Chipping away at the lung cancer genome.

William Pao, Katherine E Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22395697     DOI： 10.1038/nm.2697

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  16 in total

Review 1.  RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

Authors:  Raffaele Ciampi; Yuri E Nikiforov
Journal:  Endocrinology       Date:  2006-08-31       Impact factor: 4.736

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Activation of a novel human transforming gene, ret, by DNA rearrangement.

Authors:  M Takahashi; J Ritz; G M Cooper
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

4.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

Review 5.  Targeting RET receptor tyrosine kinase activation in cancer.

Authors:  John E Phay; Manisha H Shah
Journal:  Clin Cancer Res       Date:  2010-10-07       Impact factor: 12.531

6.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

7.  Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer.

Authors:  Juliann Chmielecki; Martin Peifer; Peilin Jia; Nicholas D Socci; Katherine Hutchinson; Agnes Viale; Zhongming Zhao; Roman K Thomas; William Pao
Journal:  Nucleic Acids Res       Date:  2010-06-29       Impact factor: 16.971

8.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

9.  KIF5B-RET fusions in lung adenocarcinoma.

Authors:  Takashi Kohno; Hitoshi Ichikawa; Yasushi Totoki; Kazuki Yasuda; Masaki Hiramoto; Takao Nammo; Hiromi Sakamoto; Koji Tsuta; Koh Furuta; Yoko Shimada; Reika Iwakawa; Hideaki Ogiwara; Takahiro Oike; Masato Enari; Aaron J Schetter; Hirokazu Okayama; Aage Haugen; Vidar Skaug; Suenori Chiku; Itaru Yamanaka; Yasuhito Arai; Shun-Ichi Watanabe; Ikuo Sekine; Seishi Ogawa; Curtis C Harris; Hitoshi Tsuda; Teruhiko Yoshida; Jun Yokota; Tatsuhiro Shibata
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

10.  Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Authors:  Samuel A Wells; Jessica E Gosnell; Robert F Gagel; Jeffrey Moley; David Pfister; Julie A Sosa; Michael Skinner; Annetta Krebs; James Vasselli; Martin Schlumberger
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544
View more
  99 in total

Review 1.  RET fusion gene: translation to personalized lung cancer therapy.

Authors:  Takashi Kohno; Koji Tsuta; Katsuya Tsuchihara; Takashi Nakaoku; Kiyotaka Yoh; Koichi Goto
Journal:  Cancer Sci       Date:  2013-10-01       Impact factor: 6.716

Review 2.  Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond.

Authors:  Christine Khoo; Toni-Maree Rogers; Andrew Fellowes; Anthony Bell; Stephen Fox
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 3.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Authors:  Takashi Kohno; Takashi Nakaoku; Koji Tsuta; Katsuya Tsuchihara; Shingo Matsumoto; Kiyotaka Yoh; Koichi Goto
Journal:  Transl Lung Cancer Res       Date:  2015-04

4.  The evolving role of the pathologist in the management of lung cancer.

Authors:  Adi F Gazdar
Journal:  Lung Cancer Manag       Date:  2012

5.  Association between the CpG island methylator phenotype and its prognostic significance in primary pulmonary adenocarcinoma.

Authors:  Young Wha Koh; Sung-Min Chun; Young-Soo Park; Joon Seon Song; Geon Kook Lee; Shin Kwang Khang; Se Jin Jang
Journal:  Tumour Biol       Date:  2016-02-11

Review 6.  New treatment options for lung adenocarcinoma--in view of molecular background.

Authors:  Nora Bittner; Gyula Ostoros; Lajos Géczi
Journal:  Pathol Oncol Res       Date:  2013-12-05       Impact factor: 3.201

Review 7.  Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer.

Authors:  Arjan Gower; Yisong Wang; Giuseppe Giaccone
Journal:  J Mol Med (Berl)       Date:  2014-05-23       Impact factor: 4.599

8.  Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung.

Authors:  Martin Frederik Dietrich; Shirley Xiao Yan; Joan Hoff Schiller
Journal:  J Thorac Oncol       Date:  2015-05       Impact factor: 15.609

9.  A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma.

Authors:  Ron Chen; Purvesh Khatri; Pawel K Mazur; Melanie Polin; Yanyan Zheng; Dedeepya Vaka; Chuong D Hoang; Joseph Shrager; Yue Xu; Silvestre Vicent; Atul J Butte; E Alejandro Sweet-Cordero
Journal:  Cancer Res       Date:  2014-03-20       Impact factor: 12.701

10.  YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway.

Authors:  Larissa A Pikor; William W Lockwood; Kelsie L Thu; Emily A Vucic; Raj Chari; Adi F Gazdar; Stephen Lam; Wan L Lam
Journal:  Cancer Res       Date:  2013-10-29       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.